Edward Lutz - Hemagen Diagnostics Independent Director
| HMGNDelisted Stock | USD 0.0001 0.00 0.00% |
Director
Mr. Edward T. Lutz is Independent Director of Hemagen Diagnostics, Inc. Mr. Lutz was the President and CEO of Lutz Advisors, Inc. since 2001. Prior to that Mr. Lutz served Tucker Anthony Sutro Capital Markets within the Investment Banking Group focusing on the bank and thrift industry. He has over thirtyfive years experience in bank regulation, mergers and acquisitions of troubled financial institutions, strategic planning and structuring financial transactions. Over the last 13 years he has specialized in investment banking and consulting to bank and thrift institutions. Mr. Lutz was a member of the board of directors of Union State Bank and U.S.B Holding Bank which as sold to KeyBank in 2008 since 2004.
| Age | 65 |
| Tenure | 20 years |
| Professional Marks | MBA |
| Phone | 443-367-5500 |
| Web | https://www.hemagen.com |
Hemagen Diagnostics Management Efficiency
The company has return on total asset (ROA) of (0.1027) % which means that it has lost $0.1027 on every $100 spent on assets. This is way below average. Hemagen Diagnostics' management efficiency ratios could be used to measure how well Hemagen Diagnostics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 9 records | DIRECTOR Age | ||
| Dennis Selkoe | Prothena plc | 73 | |
| Anders Harfstrand | Prothena plc | 60 | |
| Alec Machiels | Apellis Pharmaceuticals | 45 | |
| Sinclair Dunlop | Apellis Pharmaceuticals | 46 | |
| Paula Cobb | Prothena plc | N/A | |
| Shane Cooke | Prothena plc | 54 | |
| Stephanie OBrien | Apellis Pharmaceuticals | 59 | |
| Richard Collier | Prothena plc | 63 | |
| Christopher Henney | Prothena plc | 76 | |
Management Performance
| Return On Asset | -0.1 |
Hemagen Diagnostics Leadership Team
Elected by the shareholders, the Hemagen Diagnostics' board of directors comprises two types of representatives: Hemagen Diagnostics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hemagen. The board's role is to monitor Hemagen Diagnostics' management team and ensure that shareholders' interests are well served. Hemagen Diagnostics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hemagen Diagnostics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Hales, Executive Chairman, CEO and President Chairman of Nominating Committee, Member of Audit Committee and Member of Compensation Committee | ||
| Robert Campbell, CFO COO | ||
| Catherine Davidson, Principal Financial Officer, Principal Accounting Officer and Controller | ||
| Edward Lutz, Independent Director | ||
| Alan Cohen, Independent Director |
Hemagen Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Hemagen Diagnostics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 441.76 K | ||||
| Shares Outstanding | 15.5 M | ||||
| Price To Earning | (0.17) X | ||||
| Price To Sales | 0.1 X | ||||
| Revenue | 4.04 M | ||||
| Gross Profit | 1.61 M | ||||
| EBITDA | (273.66 K) |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Hemagen Diagnostics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Hemagen Diagnostics' short interest history, or implied volatility extrapolated from Hemagen Diagnostics options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Hemagen Diagnostics information on this page should be used as a complementary analysis to other Hemagen Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in Hemagen Pink Sheet
If you are still planning to invest in Hemagen Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hemagen Diagnostics' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Stocks Directory Find actively traded stocks across global markets | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |